KR20160113335A - 엔도뉴클레아제 활성을 포함하는 폴리펩티드 단편 및 이의 용도 - Google Patents

엔도뉴클레아제 활성을 포함하는 폴리펩티드 단편 및 이의 용도 Download PDF

Info

Publication number
KR20160113335A
KR20160113335A KR1020167026244A KR20167026244A KR20160113335A KR 20160113335 A KR20160113335 A KR 20160113335A KR 1020167026244 A KR1020167026244 A KR 1020167026244A KR 20167026244 A KR20167026244 A KR 20167026244A KR 20160113335 A KR20160113335 A KR 20160113335A
Authority
KR
South Korea
Prior art keywords
glu
leu
lys
ile
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167026244A
Other languages
English (en)
Korean (ko)
Inventor
데니스 부비에
티보 크레핀
로브 뤼그록
알렉산더 디아스
스테판 쿠삭
Original Assignee
유럽피안 몰레큘러 바이올로지 래보러토리
센트르 내쇼날 드 라 레체르체 싸이언티피크 디렉션 드 라 폴리티크 인더스트리엘르
유니버시티 죠셉 푸어리어 필리알르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유럽피안 몰레큘러 바이올로지 래보러토리, 센트르 내쇼날 드 라 레체르체 싸이언티피크 디렉션 드 라 폴리티크 인더스트리엘르, 유니버시티 죠셉 푸어리어 필리알르 filed Critical 유럽피안 몰레큘러 바이올로지 래보러토리
Publication of KR20160113335A publication Critical patent/KR20160113335A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
KR1020167026244A 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩티드 단편 및 이의 용도 Ceased KR20160113335A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20325908P 2008-12-19 2008-12-19
US61/203,259 2008-12-19
PCT/EP2009/009161 WO2010069600A2 (en) 2008-12-19 2009-12-18 Polypeptide fragments comprising endonuclease activity and their use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020117013955A Division KR20110127114A (ko) 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩타이드 단편 및 이의 용도

Publications (1)

Publication Number Publication Date
KR20160113335A true KR20160113335A (ko) 2016-09-28

Family

ID=41668407

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020117013955A Ceased KR20110127114A (ko) 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩타이드 단편 및 이의 용도
KR1020177014264A Abandoned KR20170061193A (ko) 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩티드 단편 및 이의 용도
KR1020167026244A Ceased KR20160113335A (ko) 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩티드 단편 및 이의 용도
KR1020167002571A Abandoned KR20160017132A (ko) 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩티드 단편 및 이의 용도
KR1020167002567A Ceased KR20160017131A (ko) 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩티드 단편 및 이의 용도

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020117013955A Ceased KR20110127114A (ko) 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩타이드 단편 및 이의 용도
KR1020177014264A Abandoned KR20170061193A (ko) 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩티드 단편 및 이의 용도

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020167002571A Abandoned KR20160017132A (ko) 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩티드 단편 및 이의 용도
KR1020167002567A Ceased KR20160017131A (ko) 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩티드 단편 및 이의 용도

Country Status (13)

Country Link
US (3) US20120108493A1 (cg-RX-API-DMAC7.html)
EP (2) EP2623590A3 (cg-RX-API-DMAC7.html)
JP (3) JP2012512633A (cg-RX-API-DMAC7.html)
KR (5) KR20110127114A (cg-RX-API-DMAC7.html)
CN (1) CN102449144B (cg-RX-API-DMAC7.html)
AU (1) AU2009328502B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0923134A2 (cg-RX-API-DMAC7.html)
CA (1) CA2745532A1 (cg-RX-API-DMAC7.html)
ES (1) ES2604227T3 (cg-RX-API-DMAC7.html)
IL (1) IL213360A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011006539A (cg-RX-API-DMAC7.html)
SG (1) SG172239A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010069600A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101792745B (zh) * 2009-02-04 2014-09-17 中国科学院生物物理研究所 流感病毒聚合酶亚基pa氨基端多肽的表达纯化及pa氨基端多肽的晶体结构
US8859290B2 (en) * 2011-07-22 2014-10-14 Rutgers, The State University Of New Jersey Inhibitors of influenza endonuclease activity and tools for their discovery
WO2015050170A1 (ja) * 2013-10-02 2015-04-09 学校法人 久留米大学 インフルエンザウイルス阻害薬
CN109477081A (zh) * 2016-07-07 2019-03-15 欧洲分子生物学实验室 结合细胞Pol Ⅱ C末端结构域（CTD）的病毒多肽片段及其用途
JP6918305B2 (ja) * 2017-03-10 2021-08-11 地方独立行政法人神奈川県立産業技術総合研究所 インフルエンザウイルスの増殖を阻害するモノクローナル抗体
CN114496063B (zh) * 2022-01-13 2023-05-23 北京博康健基因科技有限公司 基于天然氨基酸序列的信号肽设计与二级结构从头算建模方法和装置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000884A2 (en) * 2000-06-23 2002-01-03 American Cyanamid Company Nucleotide sequence of influenza a/udorn/72 (h3n2) genome
US20050143402A1 (en) * 2002-05-01 2005-06-30 Graham Cheetham Crystal structure of aurora-2 protein and binding pockets thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482414B1 (en) * 1998-08-13 2002-11-19 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
EP1554394B1 (en) * 2002-10-16 2009-12-16 Isis Innovation Limited Screening methods using a structural model of FIH
EP1473362A1 (en) * 2003-05-02 2004-11-03 Elan Pharmaceuticals, Inc. Glycosylation variants of BACE
US7439327B2 (en) * 2005-01-18 2008-10-21 Nuvelo, Inc. Stem cell factor-like proteins and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000884A2 (en) * 2000-06-23 2002-01-03 American Cyanamid Company Nucleotide sequence of influenza a/udorn/72 (h3n2) genome
KR20030013451A (ko) * 2000-06-23 2003-02-14 아메리칸사이아나미드컴파니 인플루엔자 에이/유돈/72(에이치3엔2) 게놈의뉴클레오타이드 서열
US20050143402A1 (en) * 2002-05-01 2005-06-30 Graham Cheetham Crystal structure of aurora-2 protein and binding pockets thereof

Also Published As

Publication number Publication date
SG172239A1 (en) 2011-07-28
ES2604227T3 (es) 2017-03-03
JP2016013124A (ja) 2016-01-28
AU2009328502B2 (en) 2015-02-05
IL213360A0 (en) 2011-07-31
EP2379715A2 (en) 2011-10-26
US9890368B2 (en) 2018-02-13
KR20110127114A (ko) 2011-11-24
BRPI0923134A2 (pt) 2017-03-28
WO2010069600A8 (en) 2011-07-21
EP2623590A2 (en) 2013-08-07
AU2009328502A1 (en) 2011-07-14
US20150105315A1 (en) 2015-04-16
WO2010069600A3 (en) 2010-08-05
JP2017205107A (ja) 2017-11-24
MX2011006539A (es) 2011-10-21
CN102449144B (zh) 2015-08-26
WO2010069600A2 (en) 2010-06-24
KR20160017132A (ko) 2016-02-15
KR20170061193A (ko) 2017-06-02
US20180010109A1 (en) 2018-01-11
CA2745532A1 (en) 2010-06-24
JP2012512633A (ja) 2012-06-07
EP2623590A3 (en) 2013-11-13
US20120108493A1 (en) 2012-05-03
CN102449144A (zh) 2012-05-09
EP2379715B1 (en) 2016-10-26
KR20160017131A (ko) 2016-02-15

Similar Documents

Publication Publication Date Title
US9045248B2 (en) Soluble fragments of influenza virus PB2 protein capable of binding RNA-cap
US20180010109A1 (en) Polypeptide fragments comprising endonuclease activity and their use
US20180044649A1 (en) Influenza a 2009 pandemic h1n1 polypeptide fragments comprising endonuclease activity and their use
HK1163166A (en) Polypeptide fragments comprising endonuclease activity and their use
HK1163166B (en) Polypeptide fragments comprising endonuclease activity and their use
HK1183501A (en) Polypeptide fragments comprising endonuclease activity and their use
HK1179985A (en) Soluble fragments of influenza virus pb2 protein capable of binding rna-cap

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160922

Application number text: 1020117013955

Filing date: 20110617

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20161024

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170121

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20171127

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180601

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20171127

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20170121

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I